Dynamic Changes of Circulating Mir-155 Expression and the Potential Application as a Non-Invasive Biomarker in Breast Cancer.
Author(s): Anwar SL, Tanjung DS, Fitria MS, Kartika AI, Sari DNI, Rakhmina D, Wardana T, Astuti I, Haryana SM, Aryandono T
Publication: Asian Pac J Cancer Prev, 2020, Vol. 21, Page 491-497
PubMed ID: 32102529 PubMed Review Paper? No
Purpose of Paper
The purpose of this paper was to compare circulating microRNA (miRNA, miR)-155 levels among patients with breast cancer and healthy controls and investigate the effects of patient age, treatment, and tumor characteristics of patients with breast cancer on levels of miR-155 in EDTA plasma.
Conclusion of Paper
Median miR-155 levels were significantly higher in plasma from breast cancer patients than healthy controls and were significantly lower after treatment than at diagnosis. Among breast cancer patients, higher median plasma miR-155 levels were found in patients >40 years old compared to those ≤40 years old but median plasma levels were still higher in breast cancer patients <40 years old than in healthy controls. However, plasma levels of miR-155 were lower in patients >40 years old than those younger than 40 after treatment. While median miR-155 levels were higher in plasma from patients with tumors >5 cm versus ≤5 cm, median miR-155 levels did not differ significantly between plasma from patients with triple negative and non-triple negative tumors, patients with tumors with good/moderate differentiation (Grade I-II), and those with poor differentiation (Grade III), or patients diagnosed at early stage (Stage I or II) versus late stage (Stage III and IV). After treatment, no significant difference in median miR-155 levels in plasma was observed between patients with tumors >5 cm versus those with tumors ≤5 cm. Patients with plasma levels of miR-155 two standard deviations above the average in healthy women had longer progression-free survival than patients with lower plasma miR-155 levels.
Studies
-
Study Purpose
The purpose of this paper was to compare circulating miR-155 levels among patients with breast cancer and healthy controls and investigate the effects of patient age, treatment, and tumor characteristics of patients with breast cancer on levels of miR-155 in EDTA plasma. EDTA peripheral blood from 102 breast cancer patients at diagnosis and 15 healthy controls. A second blood specimen was collected from 40 breast cancer patient after surgery and chemotherapy. Plasma was obtained by centrifugation of blood at 1500 rpm for 10 min at 4°C and stored at -80°C. RNA was extracted from plasma using the miRCURYTM RNA Isolation Kit. miR-155 levels quantified by real-time RT-PCR and normalized to spike in Sp6 and miR-16.
Summary of Findings:
Median miR-155 levels were significantly higher in plasma from breast cancer patients than healthy controls (18.49 ± 18 versus 1.28 ± 0.7, P<0.001) and were significantly lower after treatment than at diagnosis (2.14 ± 0.2 versus 18.49 ± 218, P<0.0001). Among breast cancer patients, higher median miR-155 levels were found in plasma from patients >40 years old compared to those ≤40 years old (28.92 ± 20.54 versus 4.19 ± 10.5, P=0.0009) but median levels were still higher in plasma from breast cancer patients <40 years old than in healthy controls (P=0.002). Interestingly, the reverse was true after treatment with lower miR-155 levels in plasma from patients >40 years old than those younger than 40 (1.1 ± 0.14 versus 2.35 ± 0.4, P=0.013). While median miR-155 levels were higher in plasma from patients with tumors >5 cm versus ≤5 cm (44.27 ± 2.6 versus 9.17 ± 6.19, P=0.03), median miR-155 levels did not differ significantly between plasma from patients with triple negative and non-triple negative tumors, patients with tumors with good/moderate differentiation (Grade I-II) and those with poor differentiation (Grade III), or patients diagnosed at early stage (Stage I or II) versus late stage (Stage III and IV). After treatment, no significant difference in median miR-155 levels in plasma was observed between patients with tumors >5 cm versus those with tumors ≤5 cm. Patients with plasma levels of miR-155 levels two standard deviations above the average in healthy women had longer progression-free survival than patients with lower plasma miR-155 levels (77 weeks versus 66 weeks, P=0.038).
Biospecimens
Preservative Types
- None (Fresh)
- Frozen
Diagnoses:
- Neoplastic - Carcinoma
- Normal
Platform:
Analyte Technology Platform RNA Real-time qRT-PCR Pre-analytical Factors:
Classification Pre-analytical Factor Value(s) Preaquisition Patient age >40 years old
≤40 years old
Preaquisition Prognostic factor Tumor Grade I-II
Tumor Grade III
<5 cm tumor
>5 cm tumor
Stage I-II at diagnosis
Stage III-IV at diagnosis
Preaquisition Diagnosis/ patient condition Breast Cancer (Luminal, Her2 or Triple negative)
Healthy